EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
15/04/2025 16:40
April 15 (Reuters) - The European Commission on Tuesday authorized the use of Eisai 4523.T and Biogen's BIIB.O drug to treat mild cognitive impairment in the early stages of Alzheimer's disease. (Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China